Document:

<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                                                                EXHIBIT 10.19(b)

                 ADDENDUM TO MANUFACTURING AND SUPPLY AGREEMENT

              This Addendum to Manufacturing and Supply Agreement (this
"Addendum"), dated as of the 1st day of August, 2001 (the "Effective Date") is
by and between JPI PHARMACEUTICA INTERNATIONAL, a division of Cilag AG
International Zug, a company duly organized and existing under the laws of
Switzerland, having its principal office in CH-6300 Zug, Kollerstrasse 38,
Switzerland ("JPI") and JANSSEN PHARMACEUTICA Inc., 1125 Trenton-Harbourton
Road, Titusville, NJ 08560, USA ("Janssen US" and, together with JPI, "Janssen")
on the one hand and Alkermes Controlled Therapeutics Inc. II, a company
organized and existing under the laws of the Commonwealth of Pennsylvania,
having its principal office at 64 Sidney Street, Cambridge MA 02139-4136, USA
("ACTII") on the other hand.

              WHEREAS, Janssen and ACTII have been collaborating for the
development of a Risperidone depot formulation incorporating ACTII's proprietary
technology concerning bioabsorbable polymer technologies and have entered into a
Development Agreement and two License Agreements related thereto; and

              WHEREAS, Janssen and ACTII entered into that certain Manufacturing
and Supply Agreement, dated August 6, 1997 (the "Supply Agreement"), with
respect to the commercial manufacture and supply of such Risperidone depot
formulation to Janssen; and

              WHEREAS, Janssen and ACTII desire to enter into this Addendum
regarding the expansion of ACTII's manufacturing facilities, and the financial
responsibilities of each of the parties in connection with such expansion, in
order to support the increased sales forecasts for such Risperidone depot
formulation; and

              WHEREAS, Janssen and ACTII further desire to enter into this
Addendum to formally provide for a collaborative effort to develop the
manufacturing facility and commercial supply of Product.

              NOW, THEREFORE, in consideration of the mutual covenants and
conditions set forth below, and intending to be legally bound hereby, the
parties agree as follows:

                            ARTICLE 1 - DEFINITIONS

       Section 1.1. Unless provided otherwise, any capitalized terms used in
this Addendum and not defined herein or below, shall have the meaning set forth
in the Supply Agreement.

              1.1.1. "Regulatory Approval" shall mean either (i) the approval of
a New Drug Application, or a comparable application, for the Product by the
United States Food and Drug Administration ("FDA"), or (ii) regulatory approval
in two (2) of the Major EU Member States (for the purpose hereof, "Major EU
Member States" means Germany, UK, France, Spain and

                                       1
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

Italy), together in each case with satisfaction of any related regulatory and
notification requirements of the FDA or such other regulatory authority.

                         ARTICLE 2 - EXPANSION PROJECT

       Section 2.1. The Project. ACTII will retain the services of an
engineering firm to develop plans to expand ACTII's manufacturing facility
located in Wilmington, Ohio (the "Project"), including detailed timelines for
completion of the Project. The Project shall include the following elements:

              2.1.1. The expansion to the current facility will be a detached
addition on the same campus as the original facility in Wilmington, Ohio (such
detached addition, including the equipment to be fitted therein, are referred to
herein as the "Expansion");

              2.1.2. The Expansion will include the utilities for a second and
third wet process line and a second filling line;

              2.1.3. Only the equipment for the second wet process line will be
installed as part of the Project; and

              2.1.4. The Project is expected to be completed by [***] and cost
approximately [***], all according to the preliminary budget and timetable set
forth on Schedule A attached hereto.

              2.1.5. The underlying assumption of the terms agreed in this
Addendum is that the Expansion will be dedicated to the manufacturing of the
Product. Notwithstanding the above, ACTII shall have the right to manufacture
other products in the Expansion, [***]. ACTII shall be entitled to proceed with
such intended manufacturing activities, provided that the Global Supply Team is
satisfied, in its reasonable judgment, that such activities will not affect the
quality (including GMP guidelines), the supply chain or capacity requirements
for the Product. In the event that ACTII proceeds with its intended
manufacturing activities, ACTII and Janssen will negotiate in good faith the
impact (if any) of such activities on the Minimum Revenues and/or the Guarantee
provided in this Addendum and modify it accordingly.

       Section 2.2. The Project Plan. Upon completion of the work by the
engineering firm, which is expected to be completed prior to July 31, 2001,
Janssen and ACTII shall meet to review the plans, budget and timetable for
completion of the Project, determine the actions to be taken by each of the
parties and to finalize the plans, budget and timetable for the Project (the
"Project Plan"). The Project Plan, including the budget, must be amended by
mutual agreement of the parties (after consultation with the Global Supply Team
(defined in Section 5.2)) if the change impacts the timeline, capacity or budget
with respect to the Product. At any time the parties amend the budget included
in the Project Plan, a corresponding amendment to the Guarantee Cap (defined in
Section 3.2) shall also be made.

       Section 2.3. Contractors and Construction. Upon approval by both parties
of the Project Plan, ACTII shall engage the services of any contractors
necessary to begin and complete

                                       2
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

actual construction of the Project and shall oversee such construction. ACTII
shall cause the timetable for completion of the Project that is part of the
Project Plan to be incorporated into all contracts and agreements with such
contractors.

              ARTICLE 3 - FINANCIAL RESPONSIBILITY FOR THE PROJECT

       Section 3.1. ACTII's Responsibility. ACTII shall be responsible for
payment of all costs and expenses related to construction of the Project,
including the design of and engineering services related to the Project, subject
to the Guarantee and Minimum Revenues (each as defined in Sections 3.2 and 3.4,
respectively).

       Section 3.2. The Guarantee. In the event that Janssen terminates
development of the Product prior to commercial launch or Janssen terminates the
Project, Janssen will reimburse ACTII for all cumulative out-of-pocket expenses
made or actually and irrevocably committed by ACTII for the Project through the
date of ACTII's receipt of written notice of such termination (such
reimbursement payment referred to herein as the "Guarantee"). The Guarantee
shall not exceed [***] (the "Guarantee Cap"), unless the parties have mutually
agreed to amend the budget and the Guarantee Cap pursuant to Section 2.2.

       Section 3.3. Refund of the Guarantee. If Janssen pays to ACTII the
Guarantee due to Janssen's termination of the Project and if the Expansion is
utilized by ACTII for another product with another corporate partner within
[***] of Janssen's termination of the Project, then ACTII shall refund that
portion of the Guarantee that is proportional to the actual utilization of the
Expansion during the [***] period which shall be paid to Janssen in installments
over the months remaining in the [***] period and so long as the utilization
continues.

       Section 3.4. Minimum Revenues. For a period of ten (10) calendar years,
Janssen shall guarantee a certain minimum amount of revenues to ACTII from
Janssen from the purchase of Product under the Supply Agreement (the "Minimum
Revenues"), unless Janssen realizes the cumulative Minimum Revenues prior to the
expansion of such 10-year period, all in accordance with this Section 3.4 and
the subsections below.

       3.4.1. Upon completion of the work by the engineering firm, which is
expected to be completed prior to July 31, 2001, Janssen and ACTII shall meet to
review the Project cost. If the aggregate Project cost is [***] or more, but
less than [***], the Minimum Revenues shall be:

                 Scenario 1: Detached Plant without filling line
                               Capital Cost: [***]
<TABLE>
<CAPTION>

  Calendar Year                        Minimum Revenue for Alkermes
   of Minimum                                   $ million
    Revenues
<S>                                    <C>
      [***]                                       [***]

</TABLE>

                                       3
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

              3.4.2. If the aggregate Project cost is less than [***] or greater
than [***], then Janssen and ACTII shall re-calculate the Minimum Revenue
amounts based on the Project cost and assumptions and preliminary Minimum
Revenue amounts set forth below.

                     (a) The Minimum Revenues are intended to derive a minimum
revenue that drives a net present value of [***] using a [***] discount rate for
ACTII's manufacturing facility investment.

                     (b) For the purpose of calculating the Minimum Revenues
under this Section 3.4, the Project cost shall not exceed [***], unless the
parties have mutually agreed to amend the budget pursuant to Section 2.2.

                     (c) The Minimum Revenues under this Section 3.4.2 shall be
calculated in substantially the same way as the Minimum Revenues under Section
3.4.1 were calculated as shown on Schedule C.

              3.4.3. First Calendar Year. The first calendar year in which
Minimum Revenues shall be guaranteed, shall begin on the earlier of (a) the
January 1 immediately following Regulatory Approval or (b) January 1, 2004,
unless the parties agree otherwise.

              3.4.4. Excess. If the aggregate amount of Product purchased by
Janssen under the Supply Agreement in any one calendar year (an "Actual Purchase
Amount") exceeds the Minimum Revenue amount for such calendar year, then such
excess (the "Excess Credit") shall be credited against any future calendar year
in which Janssen's Actual Purchase Amount is less than the Minimum Revenue
amount for such calendar year.

              3.4.5. Shortfall. If an Actual Purchase Amount is less than the
Minimum Revenue amount for the relevant calendar year, then any available Excess
Credit shall be added to the Actual Purchase Amount for such calendar year. If
the sum of Actual Purchase Amount plus any such Excess Credit are less than the
Minimum Revenue amount for such calendar year, then Janssen shall pay to ACTII
the difference between the Minimum Revenue and the sum of the Actual Purchase
Amount plus such Excess Credit (if any). A portion of an Excess Credit may be
used if only a portion is necessary to bring the sum of the Actual Purchase
Amount plus the Excess Credit up to the Minimum Revenue amount for the relevant
calendar year, in which case the balance of the Excess Credit can be used for
another future calendar year; provided, however, that the aggregate amount of
Excess Credit may only be added to an Actual Purchase Amount once.

              3.4.6. Reporting. Within seventy-five (75) days of the end of each
calendar year after Regulatory Approval, ACTII shall prepare and deliver to
Janssen a report showing (a) the Actual Purchase Amount and the Minimum Revenue
amount for such calendar year, (b) any Excess Credit added to the Actual
Purchase Amount, (c) any Excess Credit from a prior or the current calendar year
available but not added to the Actual Purchase Amount, and (d) any amount due to
ACTII under Section 3.4.5.

                                       4
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

              3.4.7. Prepayment. If (i) sales of Product are such that Janssen
determines that the expanded facility will not be utilized or (ii) Janssen
ceases to sell Product or terminates the Supply Agreement after Regulatory
Approval but before all Minimum Revenues have been achieved, then Janssen may,
in its discretion, (a) prepay the Minimum Revenues in a lump sum that is the
then net present value of the Minimum Revenues not yet achieved or (b) continue
to pay any shortfall under Minimum Revenues over time as provided in this
Section 3.4. If Janssen prepays the Minimum Revenues in a lump sum under this
Section 3.4.7 and if the Expansion is utilized by ACTII for another product
incorporating its bioabsorbable polymer technology with another corporate
partner within [***] of such prepayment, then ACTII shall refund that portion of
the lump sum payment that is proportional to the actual utilization of the
Expansion during the [***] which shall be paid to Janssen in installments over
the months remaining in the [***] and so long as the utilization continues.

             ARTICLE 4 - SECOND FILLING LINE AND FUTURE EXPANSIONS

       Section 4.1. Second Filling Line. The parties may mutually determine that
a second filling line needs to be added to the manufacturing facility. If such a
determination is made, it is anticipated that the cost of adding a second
filling line will be approximately [***]. Janssen and ACTII shall amend the
Guarantee Cap and the Minimum Revenues to take into account such additional
cost, taking into consideration the assumptions set forth in Section 3.4
(including the subsections) and the subsections below.

              4.1.1. Upon completion of the work by the engineering firm with
regard to the Project, including the second filling line, Janssen and ACTII
shall meet to review the Project cost. If the aggregate Project cost is [***] or
more, but less than [***], the Minimum Revenues, if a second filling line is
included, shall be:

<TABLE>
<CAPTION>
                                                              Scenario 2:
                                                      Detached Plant filling line
         Calendar Year                                    Capital Cost: [***]
          of Minimum                                  Minimum Revenue for Alkermes
           Revenues                                            $ million
<S>                                                 <C>
             [***]                                               [***]
</TABLE>

              4.1.2. If the aggregate Project cost, including a second filling
line, is less than [***] or greater than [***], then Janssen and ACTII shall
re-calculate the Minimum Revenue amounts based on the Project cost, including
the second filling line, and assumptions and preliminary Minimum Revenue amounts
set forth below.

                     (a) The Minimum Revenues are intended to derive a minimum
revenue that drives a net present value of [***] using a [***] discount rate for
ACTII's manufacturing facility investment.

                                       5
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                     (b) For the purpose of calculating the Minimum Revenues
under this Section 4.1.2, the Project cost shall not exceed [***], unless the
parties have mutually agreed to amend the budget pursuant to Section 2.2.

                     (c) The Minimum Revenues under this Section 4.1.2 shall be
calculated in substantially the same way as the Minimum Revenues under Section
4.1.1 were calculated as shown on Schedule C.

       Section 4.2. Reimbursement of Incremental Capital Cost. In the event that
the parties determine to include a second filling line (the "2nd Line") in the
Project, Janssen shall reimburse ACTII for the financial cost of the incremental
capital associated with the 2nd Line. To that end, Janssen shall pay to ACTII,
on a quarterly basis, an amount equal to the Prime Rate times the capital
expenses associated with the 2nd Line in excess of the capital expenses
associated with the Project excluding the 2nd Line. For purposes hereof, "Prime
Rate" shall be the prime rate as reported in the eastern edition of The Wall
Street Journal on the first day of the relevant calendar quarter on which The
Wall Street Journal is published. Janssen's obligation under this Section 4.2
shall terminate upon the occurrence of both of the following two conditions: (a)
Product delivered by ACTII to Janssen under the Supply Agreement meets or
exceeds [***] period and (b) Janssen's [***] supply forecast for Product to be
delivered by ACTII under the Supply Agreement exceeds the vial filling capacity
of the existing filling line in any [***] period in such [***] forecast.

       Section 4.3. Future Expansions. If the Global Supply Team determines that
an additional process line is required, then such additional line will be
included in the Project under conditions to be negotiated by Janssen and ACTII
at the time of such determination.

            ARTICLE 5 - MANAGEMENT OF PROJECT AND COMMERCIAL SUPPLY

       Section 5.1. Collaborative Efforts. Both parties acknowledge and agree
that the management of the commercial supply chain of Product is of critical
importance, as is (i) the timely expansion of the capacity for the manufacturing
of the bulk Product and the vial filling, (ii) the transition of the current
activities to a continuous commercial manufacturing and supply process and (iii)
the eventual commercial supply and logistics chain. Therefore, the parties shall
actively collaborate with each other, including a free exchange of expertise and
knowledge, with the following goals: (a) the timelines of expansion and supply
are respected, (b) a robust manufacturing and supply process is developed, (c)
Product will comply with all relevant quality and regulatory requirements and
(d) a continued supply of Product in accordance with current forecasts is
achieved.

       Section 5.2. Global Supply Team. ACTII shall be responsible for the
operation and management of the Project and the manufacture and supply of
Product. Notwithstanding the foregoing, a Global Supply Team shall be
established under this Section 5.2 whose goal will be to enhance and facilitate
the collaborative effort described in Section 5.1.

              5.2.1. Formation and Make-Up. Within thirty (30) days after the
Effective Date, the parties shall form the Global Supply Team. The Global Supply
Team shall consist of an

                                       6
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

equal number of representatives of each party. The Global Supply Team may
delegate its responsibilities and authority to one or more Sub-Teams. The
members of the Global Supply Team and any Sub-Teams shall have expertise in the
functional disciplines that either party believes should be represented at the
team or sub-team. The representatives of a party may be changed from time to
time at the discretion of that party upon written notification by the party
making such change to the other.

              5.2.2. Oversight of the Project and Commercial Supply. The Global
Supply Team shall be responsible for recommending actions to ACTII and Alkermes
management following periodic reviews of the Project and the commercial supply
process. Within fifteen (15) days after the receipt of the Project Plan, or any
amendment or supplement to the Project Plan, the Global Supply Team or the
appropriate Sub-Team shall meet to evaluate the Project Plan, amendment or
supplement and recommend actions. The Global Supply Team or the appropriate
Sub-Team shall periodically review the Project Plan and the progress of the
activities called for under the plan. ACTII and Alkermes management shall keep
the Global Supply Team and any Sub-Teams informed on a periodic basis of issues
and decisions affecting the commercial supply chain and the construction of the
Project and shall consult with it on such issues before making decisions
whenever possible.

              5.2.3. Meetings. The Global Supply Team and any Sub-Teams shall
meet from time to time as determined by the team members. It is expected that
the teams shall meet in person at least once in each calendar quarter. The
location of team meetings shall alternate between ACTII's and Janssen's offices
unless otherwise agreed by the parties, with the first meeting being held at
ACTII's Ohio office. Consultants and non-member employees of the parties may
attend team meetings as required to further the team's goals. Minutes of all
meetings setting forth decisions of the Global Supply Team or Sub-Team will be
prepared and circulated by the party hosting the meeting within thirty (30) days
of such meeting. Such minutes will become official when agreed to by all team
members. Each party will bear all expenses associated with attendance of its
employees and consultants at such meetings. If the team members all agree, a
meeting may be held by means of telephone conference or similar communications
equipment by means of which all persons participating in the meeting can hear
each other.

              5.2.4. Decisions. Recommendations of the Global Supply Team or
Sub-Teams shall be made by unanimous vote, with the representatives of each
party having one collective vote. If the Global Supply Team or a Sub-Team is
unable to reach a unanimous vote on any issue, then the issue shall be referred
to the President of Alkermes (or successor position) and the Senior Vice
President of Manufacturing of Janssen (or successor position) for further
discussion and resolution. These individuals shall, as soon as practicable,
attempt in good faith to resolve the dispute and, thereby, make the
recommendation on behalf of the Global Supply Team or Sub-Team. These
individuals may obtain the advice of other employees as they deem necessary or
advisable in order to make the recommendation. If such issue (a) is not resolved
within thirty (30) days after it has been referred to such persons for
resolution, (b) would cause a serious interruption of the manufacturing and
supply chain and (c) is related to the Logistic Systems, Quality System, Control
of Change, Validation, timelines of the Project Plan or

                                       7
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

commercialization ramp-up, the issue shall be resolved in accordance with the
views of the Senior Vice President of Manufacturing of Janssen. Any issue
related to the budget for the Project shall be discussed in good faith to
determine the appropriate modification or outcome and shall be agreed to by the
parties in good faith. Also, in the event ACTII is reasonably of the opinion
that Janssen's standpoint on any of the above issues could adversely affect its
obligations under the Supply Agreement, it will raise such issue and the parties
will duly consider it and its ramifications in resolving the issue at hand. In
the event Janssen nevertheless decides to proceed in accordance with its
standpoint, the parties will in good faith discuss the modifications that may be
warranted in relation to the other obligations with respect to which ACTII had
raised concerns.

       Section 5.3. Janssen Representative at the Project. In order to implement
the collaborative effort set forth under Section 5.1, Janssen will have the
right to have one or more Janssen representatives visit the Project and/or the
entire manufacturing facility in Wilmington, Ohio for short or extended periods
of time. Any such visits shall be at Janssen's expense; provided that ACTII
shall provide some accommodation at the site upon reasonable request and
provided that there is no disruption to the course of business at the site. In
the event that there is any dispute under this Section 5.3 or either party has a
concern related to the Janssen representative(s) at the manufacturing facility,
the Global Supply Team shall attempt to resolve such dispute or address such
concern.

       Section 5.4. Janssen Support. At ACTII's request, Janssen shall
reasonably assist ACTII in its contacts with manufacturing and supply
contractors and shall support ACTII in connection with its vendor relations.

                           ARTICLE 6 - MISCELLANEOUS

       Section 6.1. [***].

       Section 6.2. Bankruptcy provisions. In the event ACTII or Alkermes, Inc.
files a petition in bankruptcy, insolvency or reorganization for the benefit of
its creditors or if a receiver or trustee is appointed as provided for in
Section 10.2.3 of the Supply Agreement, ACTII shall, unless and until the Supply
Agreement would be rejected by the bankruptcy trustee in accordance with the
relevant bankruptcy codes, continue to perform all its obligations under the
Supply Agreement, including this Addendum, unless and until Janssen elects to
terminate the Supply Agreement in accordance with Section 10.2.3 of the Supply
Agreement. By October 31, 2001, ACTII shall submit to a neutral escrow agent
mutually agreeable to the parties, such as DSI Technology Escrow Services, Inc.
(the "Escrow Agent"), to hold in escrow all of the standard operating procedures
and batch records, which shall contain detailed descriptions of all steps and
operations involved in the approved Manufacturing Process (the "Escrow
Documents"). ACTII shall update the Escrow Documents annually. In the event that
Janssen terminates the Agreement under Section 10.2.3 of the Supply Agreement,
Janssen shall be free to access the Escrow Documents. Janssen, ACTII and the
Escrow Agent shall execute an escrow agreement which will control the deposit,
possession and release of the Escrow Documents and any conflict between this
Addendum and such escrow agreement shall be controlled by the escrow agreement.
Janssen, as a licensee of intellectual property rights granted under the

                                       8
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

License Agreement dated February 13, 1996, by and between Janssen US and ACT II
and the License dated February 21, 1996, by and between JPI and ACT II, shall in
addition to any rights or remedies expressly provided herein, retain any and all
of its rights under the bankruptcy code to resort to other remedies as may now
or hereafter exist at law or in equity in such event.

       Section 6.3. Amendments to the Supply Agreement. To the extent that the
provisions of this Addendum are in conflict with Sections 2.2 and 2.9 of the
Supply Agreement, Sections 2.2 and 2.9 shall be deemed to be amended by this
Addendum. The provision regarding Minimum Revenues in this Addendum shall
supersede the provisions for minimum number of Product to be purchased by
Janssen pursuant to Section 2.11 of the Supply Agreement for the ten (10)
calendar years following Regulatory Approval of Product. Except as provided in
the foregoing two sentences, all of the provisions of the Supply Agreement shall
remain in full force and effect.

       Section 6.4. Prior Agreements. The parties hereto acknowledge that this
Addendum and the Supply Agreement contain the entire agreement between the
parties pertaining to the manufacture and supply of Product in Territory and
terminates and supersedes all prior agreements, understandings, letters or other
instruments whatsoever, whether written or oral, between the parties or any of
their affiliates with respect to such matters.

                                       9
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

               IN WITNESS WHEREOF, JPI, Janssen US and ACTII have caused this
Addendum to Manufacturing and Supply Agreement to be executed by their
respective duly authorized officers on the date first set forth above.

                          JANSSEN PHARMACEUTICA INTERNATIONAL represented by
                          CILAG AG INTERNATIONAL

                          By:       /s/  Erik Rombouts
                                 ------------------------------------
                                 Name:  Erik Rombouts
                                 Title: Vice President

                          JANSSEN PHARMACEUTICA INC.

                          By:       /s/  David Y. Norton
                                 ------------------------------------
                                 Name:  David Y. Norton
                                 Title: President

                          ALKERMES CONTROLLED THERAPEUTICS INC. II

                          By:       /s/  Robert A. Breyer
                                 ------------------------------------
                                 Name:  Robert A. Breyer
                                 Title:

                                       10
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                                   SCHEDULE A
                        PRELIMINARY TIMETABLE AND BUDGET

                                      [***]

                                       11
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                                   SCHEDULE B
                    SALES FORECASTS AS OF THE EFFECTIVE DATE
                                 AS OF JUNE 2001

                                      [***]

                                       12
<PAGE>
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH "*" AND HAS BEEN FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION.

                                   SCHEDULE C
                         CALCULATION OF MINIMUM REVENUES

                                      [***]

                                       13<PAGE>
                                                                  Exhibit 10.35

                   AMENDMENT TO AGREEMENT AND PLAN OF MERGER

     This Amendment to the Agreement and Plan of Merger (the "Amendment"), dated
as of April 29, 2002, is by and among Alkermes, Inc., a Pennsylvania corporation
("Alkermes"), New Alkermes, Inc., a Pennsylvania corporation ("Parent"), Adams
Acquisition Sub, Inc., a Pennsylvania corporation and a wholly owned subsidiary
of Parent ("Adams Acquisition Sub"), Revere Acquisition Sub, LLC, a Delaware
limited liability company and a wholly owned subsidiary of Parent ("Revere
Acquisition Sub"), and Reliant Pharmaceuticals, LLC, a Delaware limited
liability company ("Reliant"), and amends the Agreement and Plan of Merger dated
March 20, 2002 between such Parties (the "Merger Agreement"). All capitalized
terms used in this Amendment without definition have the respective meanings set
forth in the Merger Agreement.

     WHEREAS, the Parties desire to amend the terms and provisions of the Merger
Agreement to change the definition of "Alkermes-Owned Reliant Units" used
therein for the purpose of including in such definition any Reliant Units owned
by Versant Acquisition LLC, a wholly owned subsidiary of Alkermes, and providing
that any such Reliant Units will be converted into Common Units immediately
following the Alkermes Merger Effective Time, but shall be otherwise unaffected
and shall continue to exist and remain outstanding as common units of Reliant
Surviving LLC after the Reliant Merger Effective Time; and

     WHEREAS, the Parties desire to amend Section 10.5 of the Merger Agreement
to clarify the intent of the Parties.

     NOW THEREFORE, the Parties, intending to be legally bound, agree as
follows:

     1.  Alkermes-Owned Reliant Units.

     (a) Section 2.2(b) of the Merger Agreement is hereby amended and restated
to be and read in full as follows:

          "(b) Alkermes-Owned Reliant Units.  All Reliant Units owned by
     Alkermes or any Subsidiary of Alkermes, including Versant Acquisition LLC,
     immediately prior to the Reliant Merger Effective Time (the "Alkermes-Owned
     Reliant Units") shall, together with all other Preferred Units, be
     converted into Common Units immediately prior to the Reliant Merger
     Effective Time, but the Common Units into which such Alkermes-Owned Reliant
     Units are converted shall be otherwise unaffected and shall continue to
     exist and remain outstanding as common units of Reliant Surviving LLC after
     the Reliant Merger Effective Time. No Parent Common Stock or other
     consideration shall be delivered to Alkermes or any of its Subsidiaries in
     respect of the Alkermes-Owned Reliant Units."

     (b) Section 2.2(c) of the Merger Agreement is hereby amended and restated
to be and read in full as follows:

          "(c) Conversion of Reliant Units.  Subject to Section 2.3(e), each
     issued and outstanding Reliant Unit (other than the Alkermes-Owned Reliant
     Units), including Reliant Restricted Units, shall be converted into the
     right to receive 1.3297 (the "Reliant Exchange Ratio") validly issued,
     fully paid and non-assessable shares of Parent Common Stock (the "Reliant
     Merger Consideration" and, together with the Alkermes Merger Consideration,
     the "Merger Consideration"). As of the Reliant Merger Effective Time, all
     Reliant Units (other than the Alkermes-Owned Reliant Units) shall no longer
     be outstanding and shall automatically be canceled and retired and shall
     cease to exist, and each holder (other than Alkermes or any Subsidiary of
     Alkermes, including Versant Acquisition LLC) of a Reliant Unit immediately
     prior to the Reliant Merger Effective Time shall cease to have any rights
     with respect thereto, except the right to receive the Reliant Merger
     Consideration, and any dividends or other distributions to which such
     holder is entitled pursuant to Section 2.3(d) and cash in lieu of
     fractional shares of Parent Common Stock to which a holder of such Reliant
     Units is entitled pursuant to Section 2.3(f), in each case to be issued or
     paid in accordance with Section 2.3(c), without interest. All shares of
     Parent Common Stock constituting the Reliant Merger Consideration shall be
     deemed to have been issued as of the Reliant Merger Effective Time."

<PAGE>

     2.  Versant Merger.  The Parties hereby acknowledge that, in accordance
with and subject to the terms of the Agreement and Plan of Merger, dated April
29, 2002 (the "Versant Merger Agreement"), among Alkermes, Parent, Versant
Acquisition LLC and Versant Reliant Corporation ("Versant"), immediately after
the Alkermes Merger Effective Time and immediately prior to the Reliant Merger
Effective Time, Versant will merge with and into Versant Acquisition LLC, with
Versant Acquisition LLC as the survivor, and the stockholders of Versant shall
receive, based upon their equity ownership of Versant, the shares of Parent
Common Stock that Versant, in its capacity as a member of Reliant, would have
received in the Reliant Merger in accordance with the provisions of Section
2.2(c) of the Merger Agreement.

     3.  Section 10.5.  Section 10.5 of the Merger Agreement is amended and
restated to be and read in full as follows:

          "Absent fraud, after Closing, the indemnification rights provided in
     this Article X, including the Escrow Indemnity Agreement and the Tax
     Indemnity Agreement, shall be the sole and exclusive remedy available to
     the Alkermes Indemnified Parties for any breach or alleged breach of this
     Agreement by Reliant."

     4.  Miscellaneous.

     (a) Governing Law.  This Amendment shall be governed by the laws of the
         State of Delaware (without giving effect to the conflict of laws
         provisions thereof).

     (b) Successors and Assigns.  This Amendment shall be binding upon and inure
         to the benefit of the Parties and their respective heirs, successors
         and permitted assigns. Nothing in this Amendment, express or implied,
         shall be construed to confer any rights or remedies upon any Person
         other than the Parties hereto, their respective successors and
         permitted assigns, Versant Acquisition LLC and as provided in Section
         12.4 of the Merger Agreement.

     (c) Further Assurances.  Each Party agrees to execute, acknowledge and
         deliver such further instruments and to do all such other acts as may
         be reasonably necessary or appropriate in order to carry out the
         purposes and intent of this Amendment.

     (d) Ratification.  Except as expressly modified by this Amendment, the
         terms and provisions of the Merger Agreement shall remain in full force
         and effect. If there is any conflict between the provisions of the
         Merger Agreement and the provisions of this Amendment, the provisions
         of this Amendment shall control.

     (e) Amendments.  This Amendment may be changed, modified or amended only by
         an agreement in writing signed by the Parties hereto.

     (f)  Counterparts.  This Amendment may be executed in counterparts, each of
          which shall be deemed an original, and all of which together shall
          constitute one and the same instrument.

                      [Signatures on the following page.]

                                       2
<PAGE>

     IN WITNESS WHEREOF, the Parties' duly authorized representatives have
executed and delivered this Amendment to the Merger Agreement as of the date and
year first above written.

                                          ALKERMES, INC.

                                          By:      /s/ JAMES M. FRATES
                                            ------------------------------------
                                          Name: James M. Frates
                                          Title:   Vice President and Chief
                                          Financial Officer

                                          NEW ALKERMES, INC.

                                          By:      /s/ JAMES M. FRATES
                                            ------------------------------------
                                          Name: James M. Frates
                                          Title:   Vice President

                                          ADAMS ACQUISITION SUB, INC.

                                          By:      /s/ JAMES M. FRATES
                                            ------------------------------------
                                          Name: James M. Frates
                                          Title:   Vice President

                                          REVERE ACQUISITION SUB, LLC

                                          By:      /s/ JAMES M. FRATES
                                            ------------------------------------
                                          Name: James M. Frates
                                          Title:   Vice President

                                          RELIANT PHARMACEUTICALS, LLC

                                          By:    /s/ JOSEPH J. KRIVULKA
                                            ------------------------------------
                                          Name: Joseph J. Krivulka
                                          Title:   President
Solely in their role as Reliant Member
Representatives:

By:      /s/ FREDERICK CRAVES
    ----------------------------------
Frederick Craves, not individually,
but solely
in his capacity as a Reliant Member
Representative

By:      /s/ MARK HOPLAMAZIAN
--------------------------------------
Mark Hoplamazian, not individually,
but solely
in his capacity as a Reliant Member
Representative

                                      3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]